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On behalf of the Editors’ Network European Society of 
Cardiology Task Force. 
The Editors´ Network of the European Society of Cardiology 
(ESC) is committed to promoting the implementation of high-
quality editorial standards among ESC National Societies 
Cardiovascular Journals (NSCJ).(1-4) NSCJ play a major role in 
disseminating high-quality scientific research. However, they 
also play a relevant role in education and harmonisation of 
clinical practice.(3) Most NSCJ are published in local languages, 
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ABSTRACT
DATA SHARING
The International Committee of Medical Journal Editors 
(ICMJE) provides recommendations to improve the 
editorial standards and scientifi c quality of biomedical 
journals. These recommendations range from uniform 
technical requirements to more complex and elusive 
editorial issues including ethical aspects of the scientifi c 
process. Recently, registration of clinical trials, confl icts 
of interest disclosure, and new criteria for authorship – 
emphasising the importance of responsibility and 
accountability – have been proposed. Last year, a new 
editorial initiative to foster sharing of clinical trial data 
was launched. This review discusses this novel initiative 
with the aim of increasing awareness among readers, 
investigators, authors and editors belonging to the 
Editors´ Network of the European Society of Cardiology. 
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but many have English editions and have gained international 
scientific recognition.(1-4) NSCJ well complement official ESC 
journals and, altogether, provide an effective means to dis-
seminate European cardiovascular research. In a globalised and 
highly competitive editorial environment, promoting high 
quality editorial standards remains of paramount importance to 
increase the scientific prestige of NSCJ.(1-4) From its conception, 
the Editors´ Network strongly advocated adherence to the 
uniform recommendations of the International Committee of 
Medical Journal Editors (ICMJE).(1) In its mission statement 
document the Editors´ Network committed to adapt NSCJ to 
follow these general editorial recommendations.(1) However, 
NSCJ are highly heterogeneous in scope and contents and 
these new recommendations should be embraced progressively, 
considering currently existing editorial policies and the editorial 
freedom of the NSCJ.(1-4) 
Ethical issues play a growing role in ensuring the credibility of 
the scientific process.(5-13) Biomedical research relies on trust. 
However, transparency also represents a major tenet in the 
scientific process.(5-8) This review will discuss the new editorial 
recommendations on data sharing issued by the ICMJE.(14) 
Novel ICMJE recommendations always appear as provocative, 
and often as too ambitious, when initially presented. Moreover, 
implementation of editorial changes is rather demanding from 
a technical and logistical viewpoint. Adherence to novel edi-
torial initiatives is challenging, not only for editors, but also for 
the entire scientific community. Therefore, many Editors have 
a natural tendency to avoid stepping ahead as early adopters 
of new “editorial experiments” and usually prefer to keep 
moving within their comfort zone until the “sea change” has 
matured.(1-4) However, experience has taught us that all editorial 
initiatives developed by the ICMJE eventually prevailed and 
played a critical role in maintaining the credibility of the scientific 
process.(9-13) Highly successful recent examples include trial 
registration, a conflicts of interest initiative and the new 
requirements for authorship.(9-13)
The novel ICMJE recommendations on data sharing(14) are 
discussed herein from a didactic perspective with the aim of 
providing new editorial insights and, hopefully, to be pro-
gressively adopted and implemented by the NSCJ. 
SHARING CLINICAL TRIAL DATA: THE NEW 
ICMJE PROPOSAL
The ICMJE considers that there is a moral obligation to 
responsibly share the data generated by clinical trials.(14) The 
rationale underlying this global endeavor is that patients have 
assumed a risk by accepting to participate in a trial. Accordingly, 
making the obtained data publicly available represents a 
responsible initiative to facilitate the advancement of science. 
Sharing the data would increase trust in the conclusions reached 
by trials. Indeed, data sharing allows for confirmation of the 
results by independent research.(14) Furthermore, new hypo-
theses may be pursued by different groups of investigators. This 
initiative may foster the leveraging of data to answer different 
research questions not contemplated in the original study. If 
science becomes an open process, then many researchers 
would benefit by taking advantage of reliable data generated 
somewhere else. Therefore, data sharing emerges as the best 
way to ensure that all the information gathered by trials is made 
freely and widely available, so that it can be readily used to 
advance scientific knowledge.(14) The use of previously collected 
data to further advance science is difficult to criticise. As 
discussed, this honours the volunteerism of the patients who 
signed up and consented to participate in a trial. 
Governments, funding agencies, scientific societies, the industry 
and even the lay society growingly demand the sharing of 
clinical trial data. Therefore, the ICMJE suggests that editors 
should help to meet this ethical obligation by devising new 
editorial policies specifically addressing this issue.(14) Proponents 
of “open science” should be pleased by this new editorial 
requirement of sharing clinical trial data.(14)
The first consideration is to clarify what a clinical trial is exactly. 
According to the ICMJE definition, a clinical trial is a study that 
prospectively assigns people to an intervention in order to 
assess the cause-and-effect relationship between that inter-
vention and the ensuing health outcome.(5) 
The ICMJE considers that sharing “de-identified” individual 
patient data should become part of the publication process of 
clinical trials.(14) This strategy protects patients’ confidentiality 
rights. The requirement, however, is restricted to the individual-
patient data underpinning the results presented in the published 
article. Importantly, a clear plan for data sharing should be 
disclosed at the time of initial trial registration and should also 
be presented at the time of manuscript submission. The 
proposal requires clinical trialists to declare that they will share 
their data publically as a prerequisite to publishing the trial.(14) 
They should promise to freely release individual patient raw 
data at the time they submit the manuscript for consideration. 
It is important to keep in mind that clinical trial registration was 
a previous ICMJE editorial initiative aimed at addressing pro-
blems related to publication bias (selective publication of posi-
tive trials), endpoints inconsistency and redundant research.(9,10) 
Potentially, public repositories provide an optimal tool, not only 
for initial trial registration, but also for individual-patient data 
sharing. From now on the plan for data-sharing would be an 
important step in the clinical trial registration initiative.(9,10,14) 
Details on whether the data would be freely available upon 
request, or only after submission of a formal application which 
will eventually be approved after an agreement is reached on 
data use conditions, should be presented. Finally, it has been 
proposed that the data should be made public no more than 
6 months after publication of the original study in the 
journal.(9,10,14) Clinicaltrials.com, a widely used non-for profit 
scientific repository,(9,10) has already adapted its registration 
platform to specifically clarify data-sharing plans at the time of 
clinical trial registration. 
Obviously, this editorial initiative may have profound con-
sequences on the planning, conducting and reporting of clinical 
trials and, in fact, may deeply influence research and publication 
strategies.(14) As a result, the idea is to implement this require-
ment for any clinical trial that begins to enroll patients 1 year 
after the official adoption of this editorial policy by the 
corresponding journal.(14) The initiative will also have major 
implications for the editorial process. Indeed, Editors are 
supposed to monitor the data sharing process and, eventually, 
address potential irregularities. These might include requests of 
clarification to the authors, notification to academic institutions, 
publication of expressions of concern or even retractions. 
Finally, the ICJME acknowledges that the rights of the investi-
gators and sponsors should be protected.(14) Moreover, credit 
to the original report should be granted by including a unique 
identifier of the data set. It is emphasised that credit should 
always be given to the original investigators who posted the 
data after publication of their research. Furthermore, additional 
investigators using these databases should request collaboration 
of the investigators which originally collected the data to ensure 
adequate data interpretation, management and analysis. 
CHALLENGES OF DATA SHARING
Although it appears clear that this initiative will further improve 
transparency and the overall integrity of the scientific literature, 
some remaining issues need to be addressed. There is inherent 
resistance to embrace open science initiatives from some 
academic institutions, or investigators, which defend the idea of 
exploiting their “own” data.(15,16) Until now clinical researchers 
were discouraged from working with clinical trial data they did 
not generate themselves.(15,16) Likewise, trialists tended to see 
trial data as their personal property and would routinely refuse 
requests for data sharing. In fact, until very recently most 
researchers and pharmaceutical industry groups were opposed 
to making raw data available after trial publication. This practice, 
however, differs from other disciplines (as genomics or 
economics) where data sharing has been common place for a 
long time.(15,16) 
Obtaining reliable, high-quality original data requires a major 
research effort. Allowing a sufficient period of time (from the 
time of article publication to the need to share the raw data) 
would give original investigators the possibility of publishing 
additional subgroup analyses from their own data.(14) This new 
proposal will further increase the pressure on academic investi-
gators which frequently do not have the required resources to 
publish their subsequent analyses and require time to prepare 
the new the manuscripts.(14) Notably, most researchers have no 
experience with the process of releasing, or dealing with, public 
data. Furthermore, the effort and resources required to organise 
the raw data in a way that would be comprehensible to other 
investigators remain a cause of major concern.(14) This would 
require technical support and adequate funding. 
Data-access to non-trial researchers may disclose problems not 
recognised by the initial investigators. Although this will increase 
transparency and, therefore, trust in trial results, it might also 
generate confusion and undue scientific controversies. It is 
difficult to envision how the new researchers will gain the 
required detailed knowledge of the complicated datasets 
enjoyed by the original trial investigators.(14) A reliable assess-
ment of the data requires a deep knowledge regarding the 
study background and an ability to properly address the many 
nuances and practical considerations. These include precise 
information on the way variables were defined, how data was 
collected and how results were finally coded and entered into 
the database. The initiative might be fraught with problems 
related to incorrect analysis resulting in inaccurate results and 
erroneous interpretations, potentially damaging science.(14) 
Finally, Editors, already deluged with work, will need to check 
that all raw data contained in the published articles is eventually 
released, as promised. Different results may emerge from mis-
conceptions regarding what data should be analysed to answer 
specific questions.(14) If there are differences in results, it will be 
difficult to decide which analysis provides the most accurate 
reflection of the data. This could generate undue “scientific 
noise”, with contradictory results and rectifications, which may 
generate confusion and frustration in the scientific community. 
Finally, this may also promote the simultaneous publication in 
several journals of conflicting results from the same database 
by different groups.(14) 
As many issues should still be clarified, the ICMJE asked for 
feedback on its preliminary editorial proposal on clinical trial 
data sharing.(14) Obviously, the initiative will only gain the 
required maturity from experience gained during its adoption 
and implementation. 
PREVIOUS INITIATIVES ON DATA SHARING
Several leading academic entities have previously worked in this 
field. The British Medical Journal pioneered an editorial initiative 
of data sharing.(17) In 2012 this policy took effect for trials on 
drugs and devices alone but, in 2015, the requirement of data 
sharing “on request” was extended to all submitted clinical 
DATA SHARING
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trials.(17) It has been proposed that individual patient data may 
also be of major value during the “peer review” process by 
permitting independent verification of the results before final 
publication.(18) Although this initiative might be of potential 
value, most reviewers are already deluged with work and this 
extra task could generate fatigue and burn out phenomena. 
In addition, many good clinical reviewers do not have the 
expertise required to manage data and to perform confirmatory 
statistical analyses.(18) Some journals, such as JAMA, previously 
developed some related editorial initiatives, including the 
request for independent statistical analyses by an academic 
statistician of industry-sponsored trials.(19) 
The World Health Organisation (WHO) and the Institute of 
Medicine (IOM) previously made important declarations on 
clinical trial transparency. In this regard, the IOM issued specific 
guidelines for trial data sharing.(20) The WHO initially presented 
a statement on public disclosure of clinical trial results and, 
subsequently, encouraged sharing of research datasets when-
ever appropriate.(21-23) More recently, the WHO developed 
global norms for sharing data and results during public health 
emergencies, with special focus on clinical, epidemiologic and 
genetic features of new infectious diseases and experimental 
therapeutics and vaccines. In emergency situations, data 
needs to be shared quickly before the information is formally 
published.(23) 
Finally, the National Health, Lung and Blood Institute (NHLBI) 
presented detailed data-sharing practices allowing public access 
to trial raw data and developed a data repository currently 
including over half a million patients from over 100 trials and 
observational studies.(24) In 2015 the NHLBI discussed its intent 
to make public the digital data from its funded trials.(24)
PLATFORMS AND REPOSITORIES
Up to 30 000 clinical trials are annually conducted worldwide 
generating a huge volume of patient-level raw data.(25) Currently, 
however, available portals for data sharing are still not ade-
quate. Most of them require a time consuming request, including 
a detailed research proposal with the study design, main 
endpoints and a statistical plan.(25) The submitted proposal is 
then reviewed by an independent research panel that decides 
whether to approve the request for data.(21,25,26) Currently, this 
process takes too long and when the data is finally obtained it 
is oftentimes not readily usable.(25) However, the means to 
facilitate data sharing from the data holder to the researcher 
may be cumbersome and challenging to implement. Some 
systems provide an electronic form or template.(21) Nevertheless, 
when these are not available a “de novo” proposal should be 
generated outlining the purpose, the statistical analysis plan, the 
research team, and potential conflicts of interest. The review 
process may come from an internal or external review panel 
selected by the data holder, or by a third party.(25-27) Finally, data 
can be shared through a public website, or by direct communi-
cation between the data holder and the researcher. In most 
cases, however, controlled access is required. Before any 
analysis is started, the reviewing of all accompanying docu-
mentation to assist the researcher in the understanding of the 
original clinical trial and the methodology used, remains critical. 
Furthermore, the data holder may require a legally binding data 
sharing agreement and should be available to provide the 
required support should questions arise.(27)
Major care should be taken to prevent the perils that may 
undermine the value of data sharing.(14) Data from trials should 
be responsibly used.(28) A recent survey from UK Clinical Trial 
Units disclosed some potential risks associated with data 
sharing.(29) These basically included (a) misuse of data, (b) 
incorrect secondary analyses, (c) resource requirements and 
(d) identification of patients.(29,30) Researchers are responsible 
for presenting the data in a format amenable for external 
secondary use. Repositories should be prepared to make raw 
data available in standardised platforms in a fully comprehen-
sive manner. Data sharing from trials with anonymised patient-
level data with associated metadata and supporting information 
should be made available to other researchers following an 
independent analysis of the research proposals. Developing and 
adopting standard approaches to protect patient privacy are 
urgently required.(14) Finally, an adequate infrastructure should 
be organised to support effective data sharing. In this regard, 
the role of the industry is significantly growing as demonstrated 
by some joint initiatives, such as the Yale University Open Data 
(YODA) project.(16,31)
Some academic research organisation consortiums particu-
larly focussed on the study of cardiovascular diseases,(32) have 
developed interesting tools for data sharing. This cardiovascular 
initiative requires presentation of a standardised request in a 
Web portal. Proposals are to be analysed by a scientific 
committee, including members designated by the consortium 
and a statistician along with the trial’s principal investigator. The 
idea is to ensure an adequate use of the data base and correct 
statistical analyses, while averting the problem of multiple 
investigators proposing the same analyses.(32) 
STATISTICAL ISSUES
Statisticians play a key role in developing data sharing strate-
gies.(19) They should be involved from the very beginning to 
organise the research strategy and the required analytical 
techniques.(19) In this scenario statisticians should move from 
their classical role as data “gate-keepers” to that of data 
“facilitators”.(19) A data sharing working group of medical 
research statisticians has recently been created from the phar-
maceutical and biotechnological industry and from academia. 
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The idea was to address the technical and statistical challenges 
of accessing research data for re-analyses. Specific techniques 
are required to ensure adequate data manipulation to convert 
the data initially collected and entered in the data base into data 
that is analytically usable. Converting raw data into standardised 
formats may be challenging. Moreover, familiarity with the 
required statistical programing language is necessary. Independ-
ent statisticians should play a major role in guiding the principles 
of re-analysis based on the researchers´ request while, at the 
same time, guarding against misleading conclusions. They should 
be fully aware that additional analysis may yield different results 
compared to the original analyses. Accordingly, they should be 
prepared to face criticism but, at the same time, they should be 
able to openly challenge previous statistical methods.(19) 
Statistical guidance may be required for appropriate inter-
pretation of results from re-analyses where different methods 
have been utilised. In particular, it is important to keep in mind 
the inherent risk of over-interpretation of the results from 
multiple subgroup analyses.(33) Likewise, documents for best 
practices in data anonymisation have been developed.(34) Statis-
ticians should also be familiar with this methodology. Risk to 
patient privacy can be mitigated by data reduction techniques. 
Data holders are responsible for generating de-identified 
datasets to protect patient privacy through masking, or general-
isation, of main identifiers. In addition, legally binding data 
sharing agreements should include a compromise not to 
attempt to identify patients.(34) In particular, it is recommended 
that data use agreements are signed by the data holder and 
researchers. Only appropriately qualified “named” researchers 
should be granted access to the data. Finally, high security levels 
should be implemented for data transferring. Resources, costs 
and effort required to make patient-level data available to third 
party research may be considerable and, therefore, adequate 
funding should be organised.(34)
CREDIT TO THE ORIGINAL AUTHORS
A clear motivation for researchers to conduct randomised 
clinical trials is the opportunity to publish different studies in 
addition to the main manuscript with the primary endpoint. 
These secondary analyses may be of major value to unravel 
new findings from the original dataset.(35,36) Many have pro-
posed that the time period to open the process of data 
sharing should be extended to 2 years, or even to 5 years in 
selected complex or large studies. This will allow precious time 
for original investigators to further scrutinise and analyse in 
depth their own data. As blinding is necessary during trial 
execution, once the study is completed the research teams 
concentrate on publishing the primary findings as soon as 
possible. Following this, there is usually a series of pre-planned 
additional analyses. These studies are organised by collaborative 
research teams from different institutions, but usually with 
relatively poor support. Secondary analyses are also very 
important for co-investigators and junior scientists. To respect 
this legitimate interest, an extension from the 6 month 
period after the primary data has been published, has been 
advocated.(35-36) 
Academia rewards scientists with recognition for making their 
discoveries public. Credit should be granted to the original 
researchers who create data sets that other investigators find 
useful.(14,15) Otherwise, original investigators may be tempted to 
consider those performing secondary analyses of their data as 
“research parasites”. Furthermore, mechanisms are required to 
ensure that the external analyses are conducted adequately and 
not merely to undermine the original findings. Direct colla-
boration between primary and secondary researchers is, 
therefore, necessary to ensure proper data analysis and 
interpretation.(14,15) The original investigators who designed and 
conducted the trial and obtained sources of founding deserve 
to receive the adequate scientific credit.(28) 
CONCLUSIONS
The data transparency revolution is here to stay. This is just 
another step ahead towards a culture of “open science” and it 
is clear that we are at the dawn of a new age.(37,38) Several 
European National Societies have already developed registry 
programmes in which the registries databases are made public 
for use by their members.(39) Major challenges and hurdles in 
the adoption and implementation of the new ICMJE recom-
mendation must still be overcome.(40) Experience gained by 
leading journals will eventually allow for a balanced compromise 
between the interests of the original researchers and that of the 
scientific community as a whole. NSCJ should progressively 
adapt their policies to increase awareness of the importance of 
data sharing and promote policies designed to enhance 
transparency in biomedical research.
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